DEL. NEWS JOURNAL LAUNCHES FIVE-PART SERIES ON YHP

PUBLISHED22 January 2013

22 January 2013

The Delaware News Journal recently launched a five-part series on the implementation of the AstraZeneca Young Health Program: IM40 throughout the state of Delaware. In partnership with the United Way of Delaware, the initiative promotes positive youth development and healthy behaviors for at-risk adolescents.

The News Journal introduced the series by noting:

AstraZeneca has partnered with the United Way to start a movement in Delaware it hopes will serve as a national model to help young people prosper by filling in the gaps of their development, whether it be social, health or educational.

Over the next two years, The News Journal and delawareonline.com will follow these youth and others like them as the program blossoms and the community learns to provide the support they need to fulfill their potential.

In the coming days, we will be highlighting some of the News Journal’s stories, including the profiles of young people from Wilmington, Kent and Sussex counties.

On the News Journal’s website, you can access an app that hosts videos of profiles on young participants, read their stories, view an interactive map of the state of Delaware and take the “40 Assets” test.

To learn about YHP: IM40, take a moment and visit www.im40.org. The recently launched site allows youth, parents, teachers and community leaders to navigate the site separately so each group receives the information that is most relevant to them.

Social Media

utility links

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.